Clinical Trials

Pancreatic Neoplasms

NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1 Suspended

43 enrolled

Pancreatic Neoplasms

NCT07491445 2026-05-14

RASolute 303

Phase 3 Recruiting

900 enrolled

Pancreatic Neoplasms

NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Phase 2 Completed

194 enrolled 16 charts

Phase 2 Not yet recruiting

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT07578337 2026-05-13

NUMANTIA-2

40 enrolled

Phase 3 Active not recruiting

Neoplasms, Pancreatic Neoplasms

NCT06608927 2026-05-08

PRISM-1

610 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT04104672 2026-05-07

ARC-8

196 enrolled

Pancreatic Neoplasms

NCT04233866 2026-05-05

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

176 enrolled

Pancreatic Neoplasms

NCT06958328 2026-05-04

LAP100

Phase 3 Recruiting

356 enrolled

Pancreatic Neoplasms

NCT07563738 2026-05-04

TEADCO

GastrointestinalOther solid neoplasmThoracic

229 enrolled

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT06390059 2026-04-30

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Completed

84 enrolled

Pancreatic Neoplasms

NCT07076121 2026-04-30

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Phase 2/3 Recruiting

470 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT02495896 2026-04-29

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

61 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT07255404 2026-04-29

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Phase 2 Recruiting

105 enrolled

Phase 3 Active not recruiting

Pancreatic Neoplasms

NCT06625320 2026-04-27

RASolute 302

500 enrolled

Pancreatic Neoplasms

NCT06423326 2026-04-22

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Phase 2 Recruiting

36 enrolled

Pancreatic Neoplasms

NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05632328 2026-04-20

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

24 enrolled

Pancreatic Neoplasms

NCT04158635 2026-04-17

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Phase 1 Recruiting

21 enrolled

Pancreatic Neoplasms

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

13 enrolled

Pancreatic Neoplasms

NCT07223047 2026-04-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

252 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06639724 2026-04-07

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Phase 1 Recruiting

36 enrolled

Pancreatic Neoplasms

NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

157 enrolled 18 charts

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

1,130 enrolled

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06360354 2026-03-31

MTAPESTRY 103

Phase 1 Recruiting

350 enrolled

Neoplasms, Pancreatic Neoplasms

NCT05586516 2026-03-30

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

16 enrolled

Phase 1 Active not recruiting

Fibrosis, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

9 enrolled

Phase 2 Not yet recruiting

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

260 enrolled

CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT04894643 2026-03-20

PARC

Phase NA Recruiting

10 enrolled

Pancreatic Neoplasms

NCT03816163 2026-03-12

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

393 enrolled